CUBICIN® (daptomycin for injection) was proven noninferior to comparators for treatment of cSSSI in adults1

Clinical success rates by infecting pathogen in CUBICIN pivotal cSSSI trials—ME population1,a

Pathogen SUCCESS RATE % (n/N)
CUBICIN Comparator
Methicillin-susceptible S. aureus 86% (170/198) 87% (180/207)
Methicillin-resistant S. aureus 75% (21/28) 69% (25/36)
Streptococcus pyogenes 94% (79/84) 91% (80/88)
Streptococcus agalactiae 85% (23/27) 76% (22/29)
Streptococcus dysgalactiae subspecies equisimilis 100% (8/8) 82% (9/11)
Enterococcus faecalis (vancomycin-susceptible only) 73% (27/37) 76% (40/53)
  1. In 2 investigator-blinded, randomized trials of CUBICIN vs standard therapy in the treatment of cSSSI, adult patients who received CUBICIN were compared with patients who received vancomycin (1 g IV q12h) or an antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin; 4 to 12 g/day IV in divided doses) for a duration of therapy of 7 to 14 days. Patients could switch to oral therapy after a minimum of 4 days of IV treatment if clinical improvement was demonstrated. Patients known to have bacteremia at baseline were excluded. The primary endpoint of the study was defined as clinical success rate, which was defined as cure or improvement sufficient to stop antibiotic treatment.

  • The clinical success rates in the ITT population (primary endpoint) in the first study were 62.5% (165/264) in patients treated with CUBICIN and 60.9% (162/266) in patients treated with comparator drugs
  • The clinical success rates in the ITT population (primary endpoint) in the second study were 80.4% (217/270) in patients treated with CUBICIN® (daptomycin for injection) and 80.5% (235/292) in patients treated with comparator drugs

Learn about the adverse reaction profile of CUBICIN in adult patients with cSSSI. »

Learn about the adverse reaction profile of CUBICIN in adult patients with bacteremia. »